Advertise Here
Deliver your message to thousands of readers every day.
Our readers are influential opinion makers - politicians, journalists and activists.
Our latest headlines
- Cavala: Musings on the California State Budget Deadlock
- Republican [Shhhh] Convention
- Assembly Budget Leadership Joins Governor Schwarzenegger in Pointing Out Irresponsibility of Republican Budget Proposal
- Barack Obama Mama goes to DNC in Denver
- California Will Comply With Medi-Cal Court Order - Will Restore Medi-Cal Provider Rates This Month
- Schwarzenegger Uses Manufactured Drought to Push Water Bond
- End of Session Summary: Environment Sees Progress But "Budget or Veto" Threat Causes Uncertainty About Bills' Future
About Us
The California Progress Report is published by Frank D. Russo, a longtime observer of and participant in California politics.
About Frank Russo.
About California Progress Report.
Got a news tip? Want to write a guest column? Contact Frank here.
Sponsors
Prescription Drug Safety Bill Stalls in California State Senate
Supporters vow to keep fighting for measure this year

By Emily Clayton
California Public Interest Research Group (CALPIRG)
Doctors, patients, consumer groups and health care advocates were dealt a setback by the state Senate this week when it failed to advance the Pharmaceutical Drug Right-to-Know Act. The legislation, SB 1683 by Senator Jack Scott (Altadena), would have required pharmaceutical companies to disclose the results of all their health studies, good and bad. It was introduced in response to the VIOXX tragedy, which was worsened by drug giant Merck’s cover-up of its own negative health studies, and other drug safety tragedies like it.
More than 50,000 Americans died from heart attacks or strokes caused by taking the pain killer VIOXX, and this legislation would have prevented or certainly limited such tragedies in the future. It was the most important consumer protection bill in California this year.
Like other measures, the bill was held in the Senate Appropriations committee and never made it to the Senate floor for a full vote. Despite minimal state costs included in the legislation and later amendments clarifying that the bill wouldn’t impose any state costs at all, the measure sat stalled.
The lobbying of the pharmaceutical industry certainly played a leading role in the bill’s failure. While legislative deadlines will prevent this specific bill from moving forward, we and the coalition who supported this measure are considering other avenues to keep the issue alive.
We understand that the pharmaceutical industry would rather not come clean by making public their health studies, but sunshine is the best disinfectant. We’re grateful for Senator Scott’s commitment to this issue and will keep working to give legislators another opportunity to do the right thing by passing a drug safety bill this year.
In addition to CALPIRG, the measure was also supported by the California Labor Federation/AFL-CIO, California Nurses Association, AARP California, American Federation of State, County and Municipal Employees, Consumers Union, Health Access, Older Women’s League, Gray Panthers, Greenlining Institute, Senior Action Network, Congress of California Seniors, California Alliance for Retired Americans and the OURx Bill of Rights Coalition.
Emily Clayton is a CALPIRG Education Fund Health Care Advocate.
CALPIRG Education Fund is an independent voice for Californians. When corporate wrongdoing threatens our health and safety or violates fundamental principles of fairness and justice, CALPIRG Education Fund stands up for California consumers. We conduct investigative research, publish reports and exposés and, when necessary, take corporate wrongdoers to court.
Comments
Post a comment
Get Email Updates
Want the California Progress Report by email? Once a week, we'll send you the latest and greatest headlines.
© 2008 California Progress Report Our copyright and fair use policy.
Powered by Mandate Media. Logo design by Jane Norling.
RSS 